Stroke:风湿性瓣膜病与卒中后不良预后相关

2016-10-24 MedSci MedSci原创

背景:风湿性心脏瓣膜病与脑血管事件风险增加相关,有风湿性二尖瓣病变(RMVD)的卒中患者的预后的研究较少。方法: 研究者对泰国卒中队列研究中RMVD与严重和常见心血管和非心血管疾病(呼吸道感染)并发症的相关性。探讨与住院死亡率相关的因素。从国家保险数据库中获得相应的数据。当前的研究中,所有住院卒中发生在2004年10月1日至2013年1月31日。比较RMVD和非RMVD患者的特征和预后。应用逻辑回

背景:风湿性心脏瓣膜病与脑血管事件风险增加相关,关于风湿性二尖瓣病变(RMVD)的卒中患者的预后的研究较少。

方法:研究者对泰国卒中队列研究中RMVD与严重和常见心血管和非心血管疾病(呼吸道感染)并发症的相关性。探讨与住院死亡率相关的因素。从国家保险数据库中获得相应的数据。


当前的研究中,所有住院卒中发生在2004年10月1日至2013年1月31日。比较RMVD和非RMVD患者的特征和预后。应用逻辑回归,倾向得分匹配,和多变量模型评估研究预后。

结果:总的来说,共有594 681例(平均年龄[SD]= 64 [ 14.5 ]年)卒中患者(缺血性卒中= 306154;出血性卒中= 195392;原因不明者= 93135)纳入本研究,其中5461例有RMVD。初步分析结果表明,校正潜在的混杂因素后,对于缺血性卒中患者, RMVD(P<0.001)与心脏骤停(OR, [ 95%CI]:2.13 = [ 1.68-2.70 ]),休克(2.13 [ 1.64-2.77 ]),心律失常(1.70 [ 1.21-2.39 ]),呼吸衰竭(2.09 [ 1.87-2.33 ]),肺炎(2 [ 1.81-2.20 ]),败血症(1.39 [ 1.19-1.63 ])的发生增加相关。出血性脑卒中患者,RMVD与(充分校正模型)呼吸衰竭(1.26 [ 1.01-1.57 ])的发生增加相关,原因不明的卒中患者,RMVD与休克(3 [ 1.46-6.14 ])、呼吸衰竭(2.70 [ 1.91-3.79 ]),和肺炎(2.42 [ 1.88-3.11 ])的发生增加相关。

结论:RMVD与急性卒中后心脏骤停、休克、心律失常、呼吸衰竭、肺炎的发生相关。

原始出处:

Wood AD, Mannu GS,et al. Rheumatic Mitral Valve Disease Is Associated With Worse Outcomes in Stroke: A Thailand National Database Study. Stroke. 2016 Oct 4.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1671265, encodeId=788716e126557, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Fri Mar 03 03:22:00 CST 2017, time=2017-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336340, encodeId=eaa413363404f, content=<a href='/topic/show?id=071820530c5' target=_blank style='color:#2F92EE;'>#不良预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20530, encryptionId=071820530c5, topicName=不良预后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Wed Oct 26 13:22:00 CST 2016, time=2016-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583486, encodeId=715e158348644, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Wed Oct 26 13:22:00 CST 2016, time=2016-10-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1671265, encodeId=788716e126557, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Fri Mar 03 03:22:00 CST 2017, time=2017-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336340, encodeId=eaa413363404f, content=<a href='/topic/show?id=071820530c5' target=_blank style='color:#2F92EE;'>#不良预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20530, encryptionId=071820530c5, topicName=不良预后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Wed Oct 26 13:22:00 CST 2016, time=2016-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583486, encodeId=715e158348644, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Wed Oct 26 13:22:00 CST 2016, time=2016-10-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1671265, encodeId=788716e126557, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Fri Mar 03 03:22:00 CST 2017, time=2017-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336340, encodeId=eaa413363404f, content=<a href='/topic/show?id=071820530c5' target=_blank style='color:#2F92EE;'>#不良预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20530, encryptionId=071820530c5, topicName=不良预后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Wed Oct 26 13:22:00 CST 2016, time=2016-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583486, encodeId=715e158348644, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Wed Oct 26 13:22:00 CST 2016, time=2016-10-26, status=1, ipAttribution=)]